The US Food and Drug Administration (FDA) has accepted for review GSK’s Biologics License Application for depemokimab.

Pharmaceutical majors AstraZeneca and GSK have partnered with competitor Takeda and nine suppliers to accelerate the adoption ...

Now biometric authentication in your home state is possible when you do GST registration in another state, GSTN Advisory on ...

The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of ...

(Alliance News) - GSK PLC on Monday said the US Food & Drug Administration has accepted for review the biologics license application for depemokimab in two indications - for asthma with type 2 ...

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

(Alliance News) - Stock prices in London opened higher on Monday, ahead of the UK manufacturing PMI and following like releases from other regions. The FTSE 100 index opened up 34.18 points, 0.4%, at ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...